Genzyme, Daiichi Sankyo Fight More Welchol ANDAs

Law360, New York (November 24, 2010, 1:29 PM EST) -- Genzyme Corp. and Daiichi Sankyo Inc. have accused Impax Laboratories Inc. and Glenmark Pharmaceuticals Ltd. of patent infringement over their efforts to manufacture and sell generic versions of the powder form of the cholesterol drug Welchol.

Genzyme and Daiichi Sankyo said in a complaint on Nov. 19 in the U.S. District Court for the District of Delaware that Impax and Glenmark were breaching two patents through abbreviated new drug applications that each has filed with the U.S. Food and Drug Administration for 1.875-gram and 3.75-gram packets...
To view the full article, register now.